TRIM33 and dermatomyositis: Mi2 subtype patients respond well to standard treatment, including corticosteroids and rituximab or other autoantibody reducing approaches (plasmapheresis) and show a good overall prognosis14–17 while anti-TIF1-γ dermatomyositis (TIF1γ subtype) is more therapy-refractory.